search
Back to results

Transurethral Myoblast Injection for Urinary Incontinence in Children With Bladder Exstrophy

Primary Purpose

Urinary Incontinence

Status
Unknown status
Phase
Phase 1
Locations
Egypt
Study Type
Interventional
Intervention
Myoblast Transplantation
Neonatal Cystourethroscope Injection
Sponsored by
Al-Azhar University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urinary Incontinence focused on measuring Urinary Incontinence, Children, Bladder Exstrophy, Extrophy -Epispadias complex,, Modern staged repair,, Bladder neck reconstruction

Eligibility Criteria

2 Years - 10 Years (Child)MaleDoes not accept healthy volunteers

Inclusion Criteria:

Gender: male.

Ages: above 2 Years old.

Patient with Urinary incontinence after successful staged repair and bladder neck reconstruction of extrophy -epispadias complex.

Absence of urinary tract infection after urine analysis and urine culture.

Serum creatinine in normal range for age.

Parent or legal guardian agrees to complete and sign the informed consent document.

-

Exclusion Criteria:

Any degree of Spinal cord injury, systemic, neuronal paralysis or sacral agenesis.

Urodynamic study demonstrating severe uninhibited bladder contractions.

Severe urethral or bladder neck stricture demonstrated during screening cystoscopy or cystogram

Cystography at the time of screening demonstrating Grade IV vesicoureteral reflux (high-grade reflux with dilation of the renal pelvis and blunting or the fornices) or Grade V vesicoureteral reflux (Grade IV findings plus loss of the papillary impression and ureteral tortuosity).

Any degree of renal scarring at the time of screening as demonstrated by DMSA or MAG3 renal scintigraphy in the presence of any grade of vesicoureteral reflux (VUR)

Renal ultrasound demonstrating Society of Fetal Urology Grade III hydronephrosis (widely split renal pelvis, renal calices uniformly dilated, no parenchymal thinning) or Grade IV hydronephrosis (Grade III dilation plus parenchymal thinning).

Positive urine culture resistant to preoperative oral antibiotic therapy. Immunocompromise patient.

Previous adverse reaction to anesthesia

-

Sites / Locations

  • Pediatric Surgery Outpatients Clinics - Al Hussien HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Myoblasts Preparation

Arm Description

Myoblast Preparation, Myoblast Transplantation & Neonatal Cystourethroscope Injection Approximately 8 to 10 gm muscle will be obtained from the rectus abdominis. Patient muscle fibers will be isolated using the fiber explant technique described by Rosenblatt et al, with some modifications. Culture conditions will be mainly adapted from Rando and Blau. After 22 days of culture myoblasts will be harvested by trypsinization and incubated in serum-free medium during the last 2 hours before injection. Immediately before injection the cell pellet will be resuspended in autologous serum and/ or platelet rich plasma (PRP).

Outcomes

Primary Outcome Measures

Clinical Parameters
Clinical assessment. Assessment of Continent Score. Maximum dry interval per day.

Secondary Outcome Measures

Clinical Changes In Bladder Behavior
Urodynamic Evaluation

Full Information

First Posted
February 26, 2014
Last Updated
February 27, 2014
Sponsor
Al-Azhar University
Collaborators
Cairo University, Affiliated Hospital to Academy of Military Medical Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT02075216
Brief Title
Transurethral Myoblast Injection for Urinary Incontinence in Children With Bladder Exstrophy
Official Title
Transurethral Autologous Myoblast Injection for Treatment of Urinary Incontinence in Children With Bladder Exstrophy
Study Type
Interventional

2. Study Status

Record Verification Date
February 2014
Overall Recruitment Status
Unknown status
Study Start Date
December 2013 (undefined)
Primary Completion Date
November 2015 (Anticipated)
Study Completion Date
December 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Al-Azhar University
Collaborators
Cairo University, Affiliated Hospital to Academy of Military Medical Sciences

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Muscle precursor cells constantly regenerate striated muscles, and include the quiescent satellite cells located beneath the basal lamina of skeletal myofibers, which are responsible for repair of the terminally differentiated striated muscle tissue. Transurethral implantation of autologous myoblasts may represent an improved alternative to synthetic bulking agents, with the unique ability to compensate for the deficient muscle fibers in the urethral sphincter. Clinical studies of cell therapy based treatment of sphincter insufficiency, using muscle derived stem cell transplantation was carried out in patients with stress incontinence revealed and confirmed the ability of cell therapy to improve the structure and contractile function of the sphincter. In this study autologous heterotopic myoblasts will be transurethrally injected in patients with bladder extrophy epispadias complex who remained incontinent after staged bladder reconstruction and bladder neck reconstruction. The aim of this study is to investigate the potential therapeutic effects of autologous myoblast injection for the treatment of children presenting with urinary incontinence after modern staged repair and bladder neck reconstruction of extrophy-epispadias complex as well as studying the safety, efficacy and durability of the procedure, and health related quality of life.
Detailed Description
Achieving urinary continence in patients with bladder extrophy epispadias complex remains a challenging urological goal. Children with bladder extrophy epispadias complex generally undergo many surgical procedures for the treatment of sphincteric incompetence, including bladder neck reconstruction, slings and bulking agent injection. The key point in most of these procedures is to enhance urethral resistance, leading to some degree of bladder outlet obstruction. However, the reported 7% to 85% continence rates in these patients may not exactly represent those children who achieve volitional voiding through the urethra, but may also include the ones with bladder augmentation and urinary diversion. Endoscopic injection of bulking agent has emerged as a therapeutic approach in the treatment of urinary incontinence (UI). this procedure seems to be economical, with shorter hospitalization and fewer major complications. On the other hand, degradation, migration, reabsorption, overbulking, bladder outlet obstruction and hypersensitivity are frequently reported complications of bulking agents. The ideal substance for periurethral injection should be durable, non immunogenic, nonmigratory and efficacious. So, transurethral implantation of autologous myoblasts may represent an improved alternative to synthetic bulking agents, with the unique ability to compensate for the deficient muscle fibers in the urethral sphincter. Patients with incontinence usually have decreased resting tone and contractility of the rhabdosphincter. In patients with bladder extrophy epispadias complex the perineal structures are dislocated laterally, and the internal and external urethral sphincters are deficient. Muscle precursor cells constantly regenerate striated muscles, and include the quiescent satellite cells located beneath the basal lamina of skeletal myofibers, which are responsible for repair of the terminally differentiated striated muscle tissue. After injury or in response to intensive physical exercise satellite cells proliferate and differentiate into myoblasts, which ultimately fuse to form new myofibers capable of muscle contraction. Considering the limited capacity of the rhabdosphincter for regeneration, the idea of urethral sphincter repair in patients with bladder extrophy epispadias COMPLEX via transurethral injection of autologous myoblasts has been suggested. The technical availability of these cells, as well as immunological acceptance and survival, makes them appropriate for this purpose. Satellite cells are committed cell lineage with restricted plasticity and do not multiply beyond the required repair needs. This property confers an acceptable measure of safety for clinical applications. The first clinical study of cell therapy based treatment of sphincter insufficiency, using muscle derived stem cell transplantation was carried out in patients with stress incontinence revealed and confirmed the ability of cell therapy to improve the structure and contractile function of the sphincter.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Incontinence
Keywords
Urinary Incontinence, Children, Bladder Exstrophy, Extrophy -Epispadias complex,, Modern staged repair,, Bladder neck reconstruction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Myoblasts Preparation
Arm Type
Experimental
Arm Description
Myoblast Preparation, Myoblast Transplantation & Neonatal Cystourethroscope Injection Approximately 8 to 10 gm muscle will be obtained from the rectus abdominis. Patient muscle fibers will be isolated using the fiber explant technique described by Rosenblatt et al, with some modifications. Culture conditions will be mainly adapted from Rando and Blau. After 22 days of culture myoblasts will be harvested by trypsinization and incubated in serum-free medium during the last 2 hours before injection. Immediately before injection the cell pellet will be resuspended in autologous serum and/ or platelet rich plasma (PRP).
Intervention Type
Procedure
Intervention Name(s)
Myoblast Transplantation
Intervention Description
For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
Intervention Type
Biological
Intervention Name(s)
Neonatal Cystourethroscope Injection
Intervention Description
4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
Primary Outcome Measure Information:
Title
Clinical Parameters
Description
Clinical assessment. Assessment of Continent Score. Maximum dry interval per day.
Time Frame
12 Weeks
Secondary Outcome Measure Information:
Title
Clinical Changes In Bladder Behavior
Description
Urodynamic Evaluation
Time Frame
24 Weeks

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Gender: male. Ages: above 2 Years old. Patient with Urinary incontinence after successful staged repair and bladder neck reconstruction of extrophy -epispadias complex. Absence of urinary tract infection after urine analysis and urine culture. Serum creatinine in normal range for age. Parent or legal guardian agrees to complete and sign the informed consent document. - Exclusion Criteria: Any degree of Spinal cord injury, systemic, neuronal paralysis or sacral agenesis. Urodynamic study demonstrating severe uninhibited bladder contractions. Severe urethral or bladder neck stricture demonstrated during screening cystoscopy or cystogram Cystography at the time of screening demonstrating Grade IV vesicoureteral reflux (high-grade reflux with dilation of the renal pelvis and blunting or the fornices) or Grade V vesicoureteral reflux (Grade IV findings plus loss of the papillary impression and ureteral tortuosity). Any degree of renal scarring at the time of screening as demonstrated by DMSA or MAG3 renal scintigraphy in the presence of any grade of vesicoureteral reflux (VUR) Renal ultrasound demonstrating Society of Fetal Urology Grade III hydronephrosis (widely split renal pelvis, renal calices uniformly dilated, no parenchymal thinning) or Grade IV hydronephrosis (Grade III dilation plus parenchymal thinning). Positive urine culture resistant to preoperative oral antibiotic therapy. Immunocompromise patient. Previous adverse reaction to anesthesia -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Abdel-Wahab El-Okby, MD
Phone
+201001478100
First Name & Middle Initial & Last Name or Official Title & Degree
Hussein Galal, MD
Phone
+201001418597
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Abdel-Wahab El-Okby, MD
Organizational Affiliation
Deaprtment of Pediatric Surgery School of Medicine Al Azhar University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Abd-Elmoneim Shawky Shams El-deen, MD
Organizational Affiliation
Department of Pediatric Surgery , School of Medicine, Al Azhar University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Hussein Galal, MD
Organizational Affiliation
Department of Urology, School of Medicine, Al Azhar University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Sayed Bakry, PhD
Organizational Affiliation
Laboratory of Molecular Biology , School of Science, Al Azhar University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Hala Gabr, MD
Organizational Affiliation
Department of Clinical Pathology , School of Medicine, Al Azhar University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Wael Abu El Khier, MD
Organizational Affiliation
Department of Clinical Pathology and Immunology, Military Academy
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Ahmed Said Sayed Bayomy, MSc
Organizational Affiliation
Department of Pediatric Surgery, School of Medicine, Al Azhar University
Official's Role
Study Chair
Facility Information:
Facility Name
Pediatric Surgery Outpatients Clinics - Al Hussien Hospital
City
Nasr City
State/Province
Cairo
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ahmed Saied, MSc
Phone
+201272453475
Email
drahmedsaid.clinic@yahoo.com
First Name & Middle Initial & Last Name & Degree
Ahmed Saied Sayed Bayomy, MSc

12. IPD Sharing Statement

Learn more about this trial

Transurethral Myoblast Injection for Urinary Incontinence in Children With Bladder Exstrophy

We'll reach out to this number within 24 hrs